


mRESVIA® (Respiratory Syncytial Virus Vaccine) • **For adults aged 60 years or older and adults aged 18 through 59 years who are at increased risk for LRTD caused by RSV¹**



Product Information Quick Guide

**The only RSV vaccine in a
ready-to-use, pre-filled syringe¹⁻³**

mRESVIA is ready to use once thawed to room temperature.¹

INDICATION

mRESVIA (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older and individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer mRESVIA to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of mRESVIA.

Please see Important Safety Information throughout and click for [mRESVIA Full Prescribing Information](#).

moderna®

Storage and Handling

Options for storing mRESVIA¹

Your mRESVIA pre-filled syringes can be stored in a freezer, refrigerator, or at room temperature, with varying storage times.

Refer to the content below for specifics.



In the freezer

-40 °F to 5 °F (-40 °C to -15 °C)



In the fridge

36 °F to 46 °F (2 °C to 8 °C)
for up to **90 days***



At room temp

46 °F to 77 °F (8 °C to 25 °C)
for up to **24 hours[†]**



Special precautions for storage¹

- **Do not** refreeze after thawing
- **Do not** refrigerate after thawing at room temperature
- Avoid exposure to direct sunlight and ultraviolet light
- Minimize exposure to room light

*Following frozen storage.¹

[†]Following frozen or refrigerated storage.¹

IMPORTANT SAFETY INFORMATION (CONT'D)

Warnings and Precautions

- **Management of Acute Allergic Reactions:** Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of mRESVIA.

Please see Important Safety Information throughout and click for [mRESVIA Full Prescribing Information](#).


Dosage and Administration

Preparing to administer mRESVIA¹


mRESVIA is a single, 0.5-mL dose pre-filled syringe containing a frozen suspension that must be thawed. At room temperature, mRESVIA is ready to use.

Refer to the images below for approximate thaw times.

Thawing 1 syringe (removed from carton) or a carton of 2 syringes



Thawing a carton of 10 syringes



Special precautions for thawing¹

- **Do not** shake mRESVIA
- **Do not** return syringes to the refrigerator after they have been thawed to room temperature
- Discard any syringes left at room temperature for over 24 hours

*Thaw in the refrigerator at 36 °F to 46 °F (2 °C to 8 °C).¹

[†]Thaw at 59 °F to 77 °F (15 °C to 25 °C), rather than at 46 °F to 77 °F (8 °C to 25 °C), as allowed for storage.¹

IMPORTANT SAFETY INFORMATION (CONT'D)

Warnings and Precautions (cont'd)

- **Syncope:** Syncope (fainting) may occur in association with administration of injectable vaccines, including mRESVIA. Procedures should be in place to avoid injury from fainting.

Please see Important Safety Information throughout and click for [mRESVIA Full Prescribing Information](#).

Administering mRESVIA with a pre-filled syringe⁴

Your mRESVIA pre-filled syringe may look and feel slightly different than a standard pre-filled syringe, as it is designed with a Luer lock.

Refer to the steps below for guidance.



< Tip cap

Luer lock >

< Plunger

Syringe barrel >

Plunger rod >

- 1 Hold the syringe vertically, with the tip cap facing upright
- 2 Grip the tip cap using one hand
- 3 Twist the tip cap counter-clockwise. **You may feel resistance.** Avoid pulling or applying pressure to the tip cap as you twist
- 4 Remove the tip cap in a slow, steady motion once released
- 5 Select a sterile Luer lock needle of appropriate length and gauge for intramuscular injection
- 6 Administer the entire dose, then discard the syringe

Always inspect your mRESVIA syringe prior to administration.¹

mRESVIA is a white to off-white suspension that may contain visible white or translucent product-related particulates. **Do not** administer the vaccine if it is discolored or contains other particulate matter.

IMPORTANT SAFETY INFORMATION (CONT'D)

Warnings and Precautions (cont'd)

- **Altered Immunocompetence:** Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to mRESVIA.

Please see Important Safety Information throughout and click for [mRESVIA Full Prescribing Information](#).

Reimbursement, Ordering, and Reporting Codes


Most payers, including Medicare Part D, process claims for mRESVIA under the pharmacy benefit.

| VACCINE TYPE | NDC 10/NDC 11 LABELER PRODUCT ID | | CVX CODE |
|--|----------------------------------|--------------------------|----------|
| Paperboard tray carton of 2 pre-filled syringes | 80777-345-63 (10-digit) | 80777-0345-63 (11-digit) | 326 |
| Blister carton of 2 pre-filled syringes | 80777-345-89 (10-digit) | 80777-0345-89 (11-digit) | |
| Paperboard tray carton of 10 pre-filled syringes | 80777-345-61 (10-digit) | 80777-0345-61 (11-digit) | |
| Blister carton of 10 pre-filled syringes | 80777-345-96 (10-digit) | 80777-0345-96 (11-digit) | |
| Pre-filled syringe | 80777-345-01 (10-digit) | 80777-0345-01 (11-digit) | |

Some payers, including Medicaid and commercial, may allow access in an office setting and process under the medical benefit.

| | | | |
|-------------------------------------|--|---|--|
| VACCINE CPT CODE (Carton) | 90683 Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use | VACCINE ADMINISTRATION CPT CODES (Carton) | 90471 Immunization administration (1 vaccine) 90472 Immunization administration (each additional vaccine) |
|-------------------------------------|--|---|--|

CPT Copyright 2025 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.



Order mRESVIA today.
It's easy on mresviapro.com/ordering


For any questions related to billing, contact Moderna
Customer Care at: [1-866-MODERNA \(1-866-663-3762\)](tel:18666633762)
8:00 AM - 8:00 PM ET

IMPORTANT SAFETY INFORMATION (CONT'D)

Adverse Reactions

In a clinical trial conducted in participants 60 years of age and older, the most commonly reported (≥10%) adverse reactions were injection-site pain (55.9%), fatigue (30.8%), headache (26.7%), myalgia (25.6%), arthralgia (21.7%), axillary (underarm) swelling or tenderness (15.2%), and chills (11.6%).

Please see Important Safety Information throughout and click for [mRESVIA Full Prescribing Information](#).



Important Safety Information

INDICATION

mRESVIA (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older and individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer mRESVIA to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of mRESVIA.

Warnings and Precautions

- **Management of Acute Allergic Reactions:** Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of mRESVIA.
- **Syncope:** Syncope (fainting) may occur in association with administration of injectable vaccines, including mRESVIA. Procedures should be in place to avoid injury from fainting.
- **Altered Immunocompetence:** Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to mRESVIA.

Adverse Reactions

In a clinical trial conducted in participants 60 years of age and older, the most commonly reported ($\geq 10\%$) adverse reactions were injection-site pain (55.9%), fatigue (30.8%), headache (26.7%), myalgia (25.6%), arthralgia (21.7%), axillary (underarm) swelling or tenderness (15.2%), and chills (11.6%).

In a clinical trial conducted in participants 18 through 59 years of age at increased risk for LRTD caused by RSV, the most commonly reported ($\geq 10\%$) adverse reactions were injection site pain (73.9%), fatigue (36.9%), headache (33.3%), myalgia (28.9%), arthralgia (22.7%), chills (19.9%), axillary (underarm) swelling or tenderness (17.1%), and nausea/vomiting (10.8%).

To report suspected adverse reactions, contact ModernaTX, Inc. at 1-866-663-3762 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

For Colorado and Connecticut price disclosure, please visit <https://modernadirect.com/wac-disclosure>.

[Click here for the mRESVIA Full Prescribing Information.](#)

CPT, Current Procedural Terminology; CVX, vaccine administered; LRTD, lower respiratory tract infection; mRNA, messenger RNA; MVX, Manufacturer of Vaccine; NDC, National Drug Code; RSV, respiratory syncytial virus.

References: **1.** mRESVIA Prescribing Information. Moderna; 2025. **2.** AREXVY Prescribing Information. GlaxoSmithKline Biologics SA. **3.** ABRYSVO Product Information. Pfizer Inc. **4.** Data on file. Moderna, Inc; 2024.